[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Ku et al., 2015 - Google Patents

Antithrombotic activities of aspalathin and nothofagin via inhibiting platelet aggregation and FIIa/FXa

Ku et al., 2015

Document ID
7892655268729149472
Author
Ku S
Lee W
Kang M
Bae J
Publication year
Publication venue
Archives of pharmacal research

External Links

Snippet

Abstract Aspalathin (Asp) and nothofagin (Not) are two major active dihydrochalcones found in green rooibos tea (Aspalathus linearis; family, Fabaceae; tribe, Crotalarieae), which have been reported for their anti-oxidant activity. Here, the anticoagulant activities of Asp and Not …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)

Similar Documents

Publication Publication Date Title
Ku et al. Antithrombotic activities of aspalathin and nothofagin via inhibiting platelet aggregation and FIIa/FXa
Lee et al. Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin
Ku et al. Antithrombotic activities of sulforaphane via inhibiting platelet aggregation and FIIa/FXa
Ku et al. Antithrombotic and antiplatelet activities of pelargonidin in vivo and in vitro
Ku et al. Antithrombotic activities of wogonin and wogonoside via inhibiting platelet aggregation
Kim et al. Antithrombotic and profibrinolytic activities of eckol and dieckol
Hemker A century of heparin: past, present and future
Levi et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation
Chen et al. Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations
Yoon et al. Antitcoagulant and antiplatelet activities of scolymoside
Fukao et al. Antithrombotic effects of odorless garlic powder both in vitro and in vivo
Ku et al. Antithrombotic and profibrinolytic activities of isorhamnetin-3-O-galactoside and hyperoside
Choi et al. Comparative effect of quercetin and quercetin‐3‐O‐β‐d‐glucoside on fibrin polymers, blood clots, and in rodent models
Lee et al. Antiplatelet effects of Spatholobus suberectus via inhibition of the glycoprotein IIb/IIIa receptor
Lee et al. Antithrombotic and antiplatelet activities of orientin in vitro and in vivo
Ku et al. Antithrombotic activities of oroxylin A in vitro and in vivo
Sikora et al. Extract of Aronia melanocarpa-modified hemostasis: in vitro studies
Ku et al. Anticoagulant activities of persicarin and isorhamnetin
Yoo et al. Antiplatelet, anticoagulant, and profibrinolytic activities of cudratricusxanthone A
Rehman et al. In vivo assessment of anticoagulant and antiplatelet effects of Syzygium cumini leaves extract in rabbits
Ku et al. Antithrombotic activities of pellitorine in vitro and in vivo
Setorki et al. Effects of apple juice on risk factors of lipid profile, inflammation and coagulation, endothelial markers and atherosclerotic lesions in high cholesterolemic rabbits
Li et al. Experimental study on the hemostatic activity of the Tibetan medicinal herb Lamiophlomis rotata
Lee et al. Anticoagulant activities of piperlonguminine in vitro and in vivo
Kim et al. Novel factor Xa inhibitor, maslinic acid, with antiplatelet aggregation activity